予防医薬品市場：流通チャネル別、専門分野別-2025-2030年の世界予測

予防医薬品市場は、2023年に3,764億9,000万米ドルと評価され、2024年には4,075億8,000万米ドルに達すると予測され、CAGR 8.74％で成長し、2030年には6,769億8,000万米ドルに達すると予測されています。

予防医薬品には、病気を未然に防ぐことを目的とした医薬品、ワクチン、サプリメント、生活習慣への介入など、幅広いものが含まれます。予防医療の必要性が高まっている背景には、慢性疾患の蔓延、医療費の増加、健康とウェルネスに対する意識の高まりがあります。最終用途は、感染症、慢性疾患管理、がん予防、母子保健など多岐にわたり、病院、診療所、研究機関、消費者直販プラットフォームなどが含まれます。同市場は、診断技術の進歩、ヘルスケア・インフラへの投資拡大、遠隔医療の導入拡大といった主要要因によって推進されています。成長の可能性は、予防接種プログラムの拡大、自己モニタリングのためのウェアラブル技術の普及、個別化予防戦略におけるAIの統合にあります。

新興国市場における最新のビジネスチャンスには、新興病原体に対する標的ワクチンの開発、遺伝子プロファイルに合わせた栄養補助食品、リアルタイムの健康データを提供するモバイルヘルスアプリケーションなどがあります。企業は研究に投資し、デジタルヘルス能力を拡大することで、これらを活用することができます。しかし、規制上のハードル、研究開発コストの高さ、ワクチンへの躊躇といった課題が成長を阻害する可能性があります。さらに、低所得地域における予防医薬品の入手しやすさや購入しやすさは、依然として大きな障壁となっています。このような課題にもかかわらず、イノベーション分野の開拓に適しているのは、疾病予測のためのバイオインフォマティクス、植物由来ワクチン、遺伝性疾病予防のためのCRISPR技術応用などです。

戦略的には、企業は精密医療イニシアチブを強化するためにハイテク企業とのコラボレーションに注力し、十分なサービスを受けていない市場へのリーチを向上させるために官民パートナーシップに関与し、科学的ブレークスルーの最前線にとどまるために継続的に研究に投資すべきです。市場の性質はダイナミックで競争が激しく、罹患率を下げるだけでなく全人的な健康管理を促進する予防対策に重点が移っています。このような複雑な要因をうまく乗り越え、新たなテクノロジーを活用し、業界を超えた協力関係を育む企業は、この進化する分野で持続的な成長を確保できると思われます。

市場力学：急速に進化する予防医薬品市場の主要市場インサイトを公開

予防医薬品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 医薬品、医療機器、治療、外科手術の価格上昇
  • 予防薬の製造に対する製薬会社の関心の高まり
  • 予防医薬品に関する教育普及のための取り組みやイベント
• 市場抑制要因
  • 予防薬に言及する地域確認の緩やかさ
• 市場機会
  • 協力的な市場エコシステム
  • オーダーメイドの処方箋をサポートする技術の進歩
• 市場の課題
  • 予防薬を引用する実証された証拠や研究の不在

ポーターの5つの力：予防医薬品市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：予防医薬品市場における外部からの影響の把握

外部マクロ環境要因は、予防医薬品市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析予防医薬品市場における競合情勢の把握

予防医薬品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス予防医薬品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、予防医薬品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨予防医薬品市場における成功への道筋を描く

予防医薬品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 医薬品、医療機器、治療、外科手術の価格上昇
    • 予防薬の製造に対する製薬会社の関心の高まり
    • 予防医薬品に関する教育を広めるための取り組みとイベント
  • 抑制要因
    • 予防薬物に関する緩く定義された地域確認
  • 機会
    • コラボレーション市場エコシステム
    • テーラーメイドソリューションの処方をサポートする技術の進歩
  • 課題
    • 予防医学を裏付ける実証された証拠や研究が存在しない
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 予防医薬品市場流通チャネル別

• 診断センター
• 病院

第7章 予防医薬品市場専門分野別

• 航空宇宙医学
• 総合予防医学
• 産業医学
• 公衆衛生

第8章 南北アメリカの予防医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の予防医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの予防医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aetna Inc.
• Affymetrix, Inc
• Cancer Prevention Pharmaceuticals, Inc
• Dilon Technologies, Inc.
• Eli Lilly and Company
• GlaxoSmithKline PLC
• McKesson Corporation
• Medtronic PLC
• Merck & Co. Inc.
• Myriad Genetics, Inc.
• Myriad Women's Health, Inc.
• Novo Nordisk A\S
• Omada Health, Inc.
• Omnicell, Inc.
• Pfizer, Inc.

LIST OF FIGURES

• FIGURE 1. PREVENTIVE MEDICINES MARKET RESEARCH PROCESS
• FIGURE 2. PREVENTIVE MEDICINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PREVENTIVE MEDICINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PREVENTIVE MEDICINES MARKET DYNAMICS
• TABLE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY AEROSPACE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GENERAL PREVENTIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY OCCUPATIONAL MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PUBLIC HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 22. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 23. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 34. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 35. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 36. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 37. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 71. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 72. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 79. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 80. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 81. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 82. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
• TABLE 101. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023

The Preventive Medicines Market was valued at USD 376.49 billion in 2023, expected to reach USD 407.58 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 676.98 billion by 2030.

Preventive medicines encompass a broad range of pharmaceuticals, vaccines, supplements, and lifestyle interventions aimed at preventing diseases before they occur. The growing necessity for preventive healthcare is driven by rising chronic disease prevalence, increasing healthcare costs, and heightened awareness around health and wellness. Its application spans across infectious diseases, chronic disease management, cancer prevention, and maternal-child health, with end-use scope including hospitals, clinics, research institutes, and direct-to-consumer platforms. The market is propelled by key factors such as technological advancements in diagnostics, increased investment in healthcare infrastructure, and the growing implementation of telemedicine. Growth potential lies in expanding immunization programs, the proliferation of wearable tech for self-monitoring, and the integration of AI in personalized preventive strategies.

Latest opportunities in the market include developing targeted vaccines for emerging pathogens, nutraceuticals tailored to genetic profiles, and mobile health applications that offer real-time health data. Companies can capitalize on these by investing in research and expanding their digital health capabilities. However, challenges such as regulatory hurdles, high R&D costs, and vaccine hesitancy can impede growth. Furthermore, the accessibility and affordability of preventive medicines in low-income regions remain significant barriers. Despite these challenges, innovation areas ripe for exploration include bioinformatics for disease prediction, plant-based vaccines, and CRISPR technology applications for hereditary disease prevention.

Strategically, businesses should focus on collaborations with tech firms to enhance precision medicine initiatives, engage in public-private partnerships to improve reach in underserved markets, and continuously invest in research to stay at the forefront of scientific breakthroughs. The nature of the market is dynamic and competitive, with emphasis shifting towards preventive measures that not only reduce incidence rates but also promote holistic health management. Companies that successfully navigate these complex factors, leveraging emerging technologies and fostering cross-industry collaborations, will likely secure sustainable growth in this evolving sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preventive Medicines Market

The Preventive Medicines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prices of medicines, medical devices, medical treatments, and surgical procedures
  • Increasing interest of pharma companies in manufacturing of preventive medicine
  • Initiatives and events to spread education about the preventive medicines
• Market Restraints
  • Loosely defined regional confirmations referring to preventive drug
• Market Opportunities
  • Collaborative market ecosystem
  • Technology advancement to support prescription of tailor made solutions
• Market Challenges
  • Absence of proven evidences or studies citing preventive medicine

Porter's Five Forces: A Strategic Tool for Navigating the Preventive Medicines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preventive Medicines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preventive Medicines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preventive Medicines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preventive Medicines Market

A detailed market share analysis in the Preventive Medicines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preventive Medicines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preventive Medicines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Preventive Medicines Market

A strategic analysis of the Preventive Medicines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Preventive Medicines Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Affymetrix, Inc, Cancer Prevention Pharmaceuticals, Inc, Dilon Technologies, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, McKesson Corporation, Medtronic PLC, Merck & Co. Inc., Myriad Genetics, Inc., Myriad Women's Health, Inc., Novo Nordisk A\S, Omada Health, Inc., Omnicell, Inc., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Preventive Medicines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Distribution Channels, market is studied across Diagnostic Centers and Hospitals.
• Based on Specialty Areas, market is studied across Aerospace Medicine, General Preventive Medicine, Occupational Medicine, and Public Health.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prices of medicines, medical devices, medical treatments, and surgical procedures
    • 5.1.1.2. Increasing interest of pharma companies in manufacturing of preventive medicine
    • 5.1.1.3. Initiatives and events to spread education about the preventive medicines
  • 5.1.2. Restraints
    • 5.1.2.1. Loosely defined regional confirmations referring to preventive drug
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative market ecosystem
    • 5.1.3.2. Technology advancement to support prescription of tailor made solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Absence of proven evidences or studies citing preventive medicine
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Preventive Medicines Market, by Distribution Channels

• 6.1. Introduction
• 6.2. Diagnostic Centers
• 6.3. Hospitals

7. Preventive Medicines Market, by Specialty Areas

• 7.1. Introduction
• 7.2. Aerospace Medicine
• 7.3. General Preventive Medicine
• 7.4. Occupational Medicine
• 7.5. Public Health

8. Americas Preventive Medicines Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Preventive Medicines Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Preventive Medicines Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aetna Inc.
• 2. Affymetrix, Inc
• 3. Cancer Prevention Pharmaceuticals, Inc
• 4. Dilon Technologies, Inc.
• 5. Eli Lilly and Company
• 6. GlaxoSmithKline PLC
• 7. McKesson Corporation
• 8. Medtronic PLC
• 9. Merck & Co. Inc.
• 10. Myriad Genetics, Inc.
• 11. Myriad Women's Health, Inc.
• 12. Novo Nordisk A\S
• 13. Omada Health, Inc.
• 14. Omnicell, Inc.
• 15. Pfizer, Inc.